-
CONFERENCE
POSTER
Comparable safety and efficacy with once-daily (QD) versus twice-daily (BID)
dosing of
lopinavir/ritonavir (LPV/r) tablets with emtricitabine (FTC) + tenofovir DF
(TDF) in antiretroviral
(ARV)-naïve, HIV-1-infected subjects: 96 week results of the randomized
tiral MO5-730
J. Gonzalez-Garcia, D. Cohen, M. Johnson, et al
PDF Poster
Abstract -
A
WEEK-IN-REVIEW-FEATURED REPORT
CONFERENCE
POSTER
Switching to
once-daily (QD) lopinavir/ritonavir (LPV/r) liquid (Liq), capsules (caps) and
tablets
(tabs): a
randomized, open label, cross-over study (CCTG 585)
G. Rieg, S. Jain,S. Sun, R. Larsen, et al
PDF Poster
Abstract -
A
WEEK-IN-REVIEW-FEATURED REPORT
CONFERENCE
POSTER
Frequency of
lipodystrophy in a large observational cohort using either LPV/r or EFV in
combination with
contemporary nucleoside analogues
J. van Lunzen, R. Pauli, A. Trein, et al
PDF Poster
Abstract -
CONFERENCE
POSTER
T-cell marker
activation, and mitochondrial membrane integrity after exposure to lopinavir,
ritonavir or
efavirenz on HIV-negative CD4+ lymphocytes
J. Scott, S. O'Barr, T. Sparrow, et al
PDF Poster
Abstract -
CONFERENCE
POSTER
Effects of
once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters
and
anthropometrics in treatment-naïve HIV-1-infected ARTEMIS patients at week 96
E. Baraldi, J. Morales-Ramírez, S. Schneider, et al
PDF Poster
Abstract -
CONFERENCE
POSTER
Virologic and
immunologic responses to efavirenz or boosted lopinavir as first therapy for
patients with
HIV in the Swiss HIV Cohort Study (SHCS)
H.C. Bucher J. Young, H. Günthard, et al
PDF Poster
Abstract -
CONFERENCE
POSTER
Differences in
lopinavir and ritonavir plasma concentration do not explain greater increase
in
LDLc in patients receiving lopinavir/ritonavir with nevirapine compared to
lopinavir/ritonavir with
zidovudine/lamivudine
W.F.W. Bierman, M.G.A. van Vonderen. D.M. Burger, et al
PDF Poster
Abstract -
CONFERENCE POSTER
Phenotypic susceptibility and drug resistance profile of HIV-1 B, C and AG
clones selected with
atazanavir, lopinavir and nelfinavir
I. Lisovsky, J.L. Martinez Cajas, M. Oliveira, D. Moisi, et al
PDF Poster
Abstract -
Changes in lipid profiles after
switching young children from a suppressive lopinavir/ritonavir-based
regimen to a nevirapine-based regimen
R. Strehlau, A. Coovadia, L. Martens, et
al
Abstract
-
Lopinavir/ritonavir-based second line antiretroviral treatment in children at
National Pediatric
Hospital, Phnom
Penh, Cambodia
S. Sophan. U. Vibol, H. Chantheany, et al
Abstract
-
How well do the
revised World Health Organisation weight-based dosing guidelines for
lopinavir/ritonavir
in infants and children correlate with body surface area-based dosing
recommendations?
J. Nuttall, B. Eley, M.-A. Davies, et al
Abstract
-
Simplifying
antiretroviral treatment in virally suppressed children by switching from
double boosted
protease inhibitors to lopinavir/ritonavir monotherapy
T. Bunupuradah, P. Lumbiganon, T. Puthanakit, et al
Abstract
-
Pharmacokinetics, placental transfer and infant outcome in 56 LPV/r exposed
pregnancies
M. Sovric, A. Gingelmaier, R. Kaestner, et al
Abstract
-
Lopinavir/ritonavir (LPV/r)- compared to nevirapine (NVP)-based ART
following receipt of single-dose
nevirapine (sdNVP) for prevention of mother-to-child HIV transmission in
South Africa: a
cost-effectiveness analysis of the OCTANE (ACTG A5208) trial
A. Ciaranello. K. Freedberg, J. Chu, et al
Abstract
-
Nevirapine
(NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in
single dose
nevirapine (sdNVP)-exposed
HIV-infected infants: preliminary results from the IMPAACT P1060 trial
P. Palumbo, A. Violari J. Lindsey, et al
Abstract
-
The impact of
raltegravir and lopinavir/ritonavir on lipids, adiponectin and peripheral
glucose
disposal in HIV negative subjects
P. Randell, A. Jackson, S. Mandalia, et al
Abstract
-
Analysis of the
mean increase in CD4 cell counts and viral load decrease between different
subtypes C, CRF31_BC, B and F after initial antiretroviral therapy in a Porto
Alegre HIV clinic,
southern of Brazil
C. Nunes, C. Dias, I. Lamego, L. Brigido
Abstract
-
Switching to
once-daily (QD) lopinavir/ritonavir (LPV/r) liquid (Liq), capsules (caps) and
tablets
(tabs): a
randomized, ppen label, cross-over study (CCTG 585)
G. Rieg, S. Jain,S. Sun, R. Larsen, et al
Abstract
-
Frequency of
lipodystrophy in a large observational cohort using either LPV/r or EFV in
combination with
contemporary nucleoside analogues
J. van Lunzen, R. Pauli, A. Trein, et al
Abstract
-
Efficacy and
safety of atazanavir/r vs. lopinavir/r in treatment-naïve patients with
advanced
disease: CASTLE
study 96-week results
J. Uy, R. Yang, V. Wirtz, et al
-
Cost
effectiveness of switching to second line therapy with lopinavir/ritonavir
(LPV/r) in Kenya
and Uganda
K.N. Simpson, B. Dietz, S. Rahim, R. Rajagopalan
Abstract
-
Kivexa versus truvada: similar virological outcomes in ART-naïve patients
starting a l
opinavir/ritonavir-based regimen - 48-week-data from the STAR and Stella
cohorts
C. Koegl, A. Baumgarten, B. Bieniek, et al
Abstract
-
Tolerability of
post-exposure prophylaxis (PEP) of HIV infection with the combination of
tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation (Truvada
+ Kaletra)
W. Tosini,, P. Muller, T. Prazuck
Abstract
|
|
|
|
|
|
|
 |
|
Documents identified with this icon are in
Portable Document Format (PDF) and require the
